The effect of polymorphisms of MTHER gene and vitamin B on hyperhomocysteinemia

Abstract

The relationship between hyperhomocysteinemia and coronary artery disease (CAD) was investigated and the influence of environmental factors (Folate, VitB12) and genetic factors [N5, N10-methylenetetrahydrofolate reductase gene (MTHFR) or MTHFR gene mutation] on plasma homocysteine (Hcy) levels and the risk of CAD observed. Fifty-one CAD patients and 30 CAD-free subjects were recruited in the study. The polymorphisms of MTHFR gene were analyzed by PCR-RFLP and plasma total Hcy levels were measured by high performance liquid chromatography with fluorescence detection. Plasma folate and vitamin B12 concentrations were measured by an automated chemiluminescence method. It was found that mean total plasma Hcy concentrations were significantly higher in CAD patients than in CAD-free subjects (P<0. 01). The differences were also apparent among the three genotypes of MTHFR gene in CAD group (P<0. 05). There was no significant difference in the genotype distributions and allele frequencies between the two groups. A strong inverse correlation was found between folate or vitamin B12 and plasma Hcy levels according to MTHFR genotype (P<0. 01). It was concluded that hyperhomocysteinemia is a new independent risk factor for CAD. However, MTHFR gene mutation alone does not relate significantly to the morbidity of CAD since hyperhomocysteinemia and its influence on the risk of CAD are decided by both environmental and genetic factors. Supplementary treatment with vitamins B can effectively lower the plasma levels of Hcy, thus maybe reduceing the risk of CAD.

Keywords

hyperhomocysteinemia / coronary artery disease / gene / Vitamin B12 / folate

References

[1] StampferM J, MalinowM R, WillettW C, et al.. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA, 1992, 268(7): 881-881

[2] GirelliB D, FrisoS, TrabettiE, et al.. Methylenetetrahydrofolate reductase C677 T mutation, plasma homocysteine, and folate in subjects from Northern Italy with or without angiographically documented severe coronary atherosclerotic disease: evidence for an important genetic-environmental interaction. Blood, 1998, 91(11): 4158-4158

[3] KangS S, PassenE L, RuggieN, et al.. Thermolabile defect of methylenete-trahydrofolate reductase in coronary artery disease. Circulation, 1993, 88: 1463-1463

[4] FrosstP, BlamH J, MilosR, et al.. A candidate genetic risk factor for vascular disease; a common mutation in methylenetetrahydrofolate reductase. Nat Genet, 1995, 10: 111-111

[5] VerhoeffB J, TripM D, PrinsM H, et al.. The effect of a common methylenetetrahydrofolate reductase mutation on levels of homocysteine, folate, vitamin B12 and on the risk of premature atherosclerosis. Atherosclerosis, 1998, 141: 161-161

[6] VesterB, RasmussenK. High performance liquid chromatography method for rapid and accurate determination of homocysteine in plasma and serum. Eur J Clin Chem Clin Biochem, 1991, 29: 549-549

[7] SorienteL, CoppolaA, MadonnaP, et al.. Homozygous C677 T mutation of the 5,10-methylenetetrahydrofolate reductase gene and hyperhomocysteinemia in Italian patients with a history of early-onset ischemic stroke. Stroke, 1998, 29(4): 869-869

[8] DelougheryT G, EvansA, SadeghiA, et al.. Common mutation in methylenetetrahydrofolate reductase. Correlation with homocysteine metabolism and late-onset vascular disease. Circulation, 1996, 94(12): 3074-3074

[9] LentzS R. Homocysteine and vascular disfunction. Review. Life Science, 1997, 61: 1205-1205

[10] TsaiJ C, PerrellaM A, YoshizumiM, et al.. Promotion of vascular smooth muscle cell growth by homocysteime: a link to atherosclerosis. Proc Natl Acad Sci USA, 1994, 91: 6369-6369

[11] Harpel P C, Zhang X X, Borth W. Homocysteine and hemostasis; pathogenetic mechanisms predisposing to thrombosis. J Nutr, 1996, 126(4 suppl): 1285s

[12] LiaoJ K, ShinW S, LeeW Y. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem, 1995, 270: 319-319

[13] HarpelP C, ChangV T, BorthW. Homocysteine and other sulphydryl compounds enhance the binding of lipoprotein (a) to fibrin: a potential biochemical link between thrombosis, atherogenesis and sulphydryl compound metabolism. Proc Natl Acad Sci USA, 1989, 10: 193-193

[14] KochH G, GoebelerM, MarquardtT, et al.. The redox status of aminothiols as a clue to homocysteine-induced vascular damage?. Eur J Pediatr, 1998, 157(2): 102-102

[15] BoersG. Moderate hyperhomocysteineamia and vascular disease: evidence, relevance and the effect of treatment. Eur J Pediatr, 1998, 157(2): 127-127

[16] KluijtmansL A J, KasteleinJ J P, LindemansJ, et al.. Thermolabile methylenetetrahydrofolate reductase in coronary artery disease. Circulation, 1997, 96(8): 573-573

[17] MoritaH, TaguchiJ, KuriharaH, et al.. Genetic polymorphism of 5, 10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation, 1997, 95(8): 2032-2032